Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: A case report

Diabetes and Metabolism

Volumn 35, Issue 2, 2009, Pages 151-154

  Collet Gaudillat, C ^a   Billon Bancel, A ^a   Beressi, J P ^a  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

A type lamin mutation; Diabetes mellitus; Dunnigan lipoatrophy; Insulin resistance

Indexed keywords

ATORVASTATIN; FENOFIBRATE; INSULIN GLARGINE; INSULIN LISPRO; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SPIRONOLACTONE;

ACANTHOSIS NIGRICANS; ADULT; ARTICLE; CASE REPORT; CHOLESTASIS; CYTOLYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; FOLLOW UP; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC REGULATION; MOLECULAR GENETICS; MYALGIA;

ADIPOSE TISSUE; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LAMIN TYPE A; LIPODYSTROPHY, FAMILIAL PARTIAL; METFORMIN; MIDDLE AGED; PORTUGAL; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 64149126283     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.01.001     Document Type: Article

References (10)

1. Hegele R.A. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome. Mol Genet Metab 71 (2000) 539-544
2. Donadille B., Lascols O., Capeau J., and Vigouroux C. Etiological investigations in apparent type 2 diabetes: when to search for lamin A/C mutations?. Diabetes Metab 31 (2005) 527-532
3. Young J., Morbois-Trabut L., Couzinet B., lascols O., Dion E., Beréziat V., et al. Type A insulin resistance syndrome revealing a novel lamin A mutation. Diabetes 54 (2005) 1873-1878
4. Owen K.R., Donohoe M., Ellard S., and Hattersley A.T. Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 20 (2003) 823-827
5. Vantyghem M.C., Pigny P., Maurage C.A., Rouaix-Emery N., Stojkovic T., Cuisset J.M., et al. Patients with familial partial lipodystrophy of the Dunnigan Type due to LMNA R482W mutation show muscular and cardiac abnormalities. J Clin Endocrinol Metab 89 (2004) 5337-5346
6. Ludtke A., Heck K., Genschel J., Mehnert H., Spuler S., Worman H.J., et al. Long-term treatment experience in a subject with Dunnigan type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 22 (2005) 1611-1613
7. Moreau F., Boullu- Sanchis S., Vigouroux C., Lucescu C., Lascols O., Sapin R., et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab 33 (2007) 385-389
8. Sleilati G.G., Leff T., Bonnett J.W., and Hegele R.A. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Endocr Pract 13 (2007) 656-661
9. Maraldi N.M., Capanni C., Mattioli E., Columbaro M., Squarzoni S., Parnaik W.K., et al. A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome. Acta Biomed 78 (2007) 2007-2015
10. Park J., Javor E., Cochran E., DePaoli A., and Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 56 (2007) 508-516